Inhibition of IL-6 for the treatment of inflammatory diseases

Norihiro Nishimoto; Tadamitsu Kishimoto

doi:10.1016/j.coph.2004.03.005

Inhibition of IL-6 for the treatment of inflammatory diseases

Curr Opin Pharmacol. 2004 Aug;4(4):386-91. doi: 10.1016/j.coph.2004.03.005.

Authors

Norihiro Nishimoto¹, Tadamitsu Kishimoto

Affiliation

¹ Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita-City, Osaka, 565-0871, Japan. norihiro@fbs.osaka-u.ac.jp

PMID: 15251133
DOI: 10.1016/j.coph.2004.03.005

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with various biological activities. Deregulated overproduction of IL-6 has been found to play pathological roles in chronic inflammatory diseases such as rheumatoid arthritis, Castleman's disease, juvenile idiopathic arthritis and Crohn's disease. Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies.

Publication types

Review

MeSH terms

Animals
Antibodies / therapeutic use
Arthritis, Rheumatoid / therapy
Castleman Disease / therapy
Crohn Disease / therapy
Humans
Inflammation / therapy*
Interleukin-6 / antagonists & inhibitors*
Interleukin-6 / physiology
Receptors, Interleukin-6 / antagonists & inhibitors
Still's Disease, Adult-Onset / therapy

Substances

Antibodies
Interleukin-6
Receptors, Interleukin-6